<div>
 <ul>
 <li>
 
 UK-based AI drug discovery company BenevolentAI and Exscientia have entered into strategic partnerships with pharmaceutical company Merck to identify and develop new compounds against three targets provided by Merck through hit identification to the pre-clinical stage.
 
 </li>
 <li>
 
 The collaboration will allow Merck to leverage BenevolentAI's AI platform and team to identify and develop novel compounds for drug development, initially targeting oncology, neurology, and immunology. BenevolentAI will use its AI chemistry design tools and wet lab facility to deliver small molecule drug development candidates into the Merck pipeline.
 
 </li>
 <li>
 
 Through the partnership, BenevolentAI will receive upfront and milestone payments of up to USD 594 million and royalties on net sales of any commercialized products.&nbsp;
 
 </li>
 <li>
 
 In addition, Merck will also combine Exscientia's AI-driven precision drug design capabilities with its own disease expertise in oncology and neuroinflammation for the discovery of novel small molecule drug candidates.&nbsp;
 
 </li>
 <li>
 
 Exscientia will receive an upfront cash payment of USD 20 million and is eligible for milestone payments of up to USD 674 million in discovery, development, regulatory, and sales-based milestones for three projects, in addition to single- to double-digit royalty payments on net sales.
 
 </li>
 </ul>
 
 
</div>

<div>
 
 <a href="https://www.merckgroup.com/en/news/two-ai-partnerships-in-healthcare-20-09-2023.html">
 Company Press Release - Merck
 </a>
 
 
 <a href="https://investors.exscientia.ai/press-releases/press-release-details/2023/Exscientia-Announces-AI-Drug-Discovery-Collaboration-with-Merck-KGaA-Darmstadt-Germany/default.aspx">
 Company Press Release - Exscientia
 </a>
 
 
 <a href="https://www.benevolent.com/news-and-media/press-releases-and-in-media/benevolentai-signs-strategic-collaboration-merck/">
 Company Press Release - BenevolentAI
 </a>
 
 
 <a href="https://european-biotechnology.com/up-to-date/latest-news/news/benevolentai-ltd-inks-us594m-partnership-with-merck-kgaa.html">
 European Biotechnology
 </a>
 
</div>

Precision Medicine

AI drug discovery companies BenevolentAI and Exscientia have partnered with pharmaceutical company Merck to identify and develop new compounds for drug development. BenevolentAI will use its AI platform and chemistry design tools to deliver small molecule drug development candidates for Merck, with upfront and milestone payments of up to $594 million and royalties on any commercialized products. Exscientia will combine its AI-driven precision drug design capabilities with Merck’s disease expertise in oncology and neuroinflammation, receiving an upfront payment of $20 million and potential milestone payments of up to $674 million, as well as royalty payments on net sales.

Merck enters into drug discovery partnerships with BenevolentAI and Exscientia

Artificial intelligence is identifying and testing new therapies faster than ever.

AI Drug Discovery

BenevolentAI and Exscientia have partnered with pharmaceutical company Merck to identify and develop new compounds against three targets provided by Merck. BenevolentAI's AI platform will be used to identify and develop novel compounds for drug development in the fields of oncology, neurology, and immunology. In return, BenevolentAI will receive upfront and milestone payments of up to $594 million, as well as royalties on net sales. Exscientia will also work with Merck to discover small molecule drug candidates using AI-driven precision drug design capabilities, receiving an upfront cash payment of $20 million and potential milestone payments of up to $674 million, as well as royalty payments.

All Updates

Merck enters into drug discovery partnerships with BenevolentAI and Exscientia

Merck enters into drug discovery partnerships with BenevolentAI and Exscientia

BenevolentAI identifies new target for AstraZeneca

BenevolentAI completes SPAC deal; debuts on Euronext Amsterdam

BenevolentAI joins the World Economic Forum’s global innovators community

BenevolentAI partners with DNDi for dengue-focused drug research

BenevolentAI to go public via EUR 1.5 billion SPAC deal